孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床观察

发布时间：2018-05-10 10:08

本文选题：急性细菌性支气管炎 + 咳嗽　；参考：《中国药房》2017年29期

【摘要】：目的:观察孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床疗效及安全性。方法:选取2016年1-12月宁波市鄞州区钱湖医院门诊收治的急性细菌性支气管炎咳嗽患者139例,按照随机数字表法分为对照组(69例)与观察组(70例)。对照组患者给予盐酸莫西沙星片0.4 g,po,qd;观察组患者在对照组基础上给予孟鲁司特钠片10 mg,po,每晚1次。两组患者疗程均为6 d。比较两组患者治疗前后的咳嗽症状评分、外周血白细胞计数(WBC)和C反应蛋白(CRP)含量,观察临床疗效、不良反应发生情况和临床转归情况。结果:治疗前,两组患者的咳嗽症状评分、外周血WBC和CRP含量比较,差异均无统计学意义(P0.05)。治疗后,两组患者的咳嗽症状评分、外周血WBC和CRP含量均较治疗前显著降低,且观察组治疗3 d后的咳嗽症状评分显著低于同期对照组,差异均有统计学意义(P0.05);但治疗6 d后两组患者上述各项指标比较,差异均无统计学意义(P0.05)。观察组患者的治愈率为64.29%,显著高于对照组的44.93%,差异有统计学意义(P0.05);观察组和对照组患者的有效率分别为97.14%和97.10%,组间比较差异无统计学意义(P0.05)。两组患者治疗期间均未见明显不良反应发生,且临床转归良好。结论:孟鲁司特联合莫西沙星不但可有效地减轻急性细菌性支气管炎患者的咳嗽症状和炎症反应,还可明显提高治愈率,且安全性较高。
[Abstract]:Objective: To observe the clinical efficacy and safety of Montelukast Combined with moxifloxacin in the treatment of acute bacterial bronchitis and cough. Methods: 139 patients with acute bacterial bronchitis treated in the outpatient clinic of Yinzhou District Qian Hu hospital in Ningbo, Ningbo, 2016, were divided into the control group (69 cases) and the observation group (70 cases) according to the random digital table method. The patients were given Moxifloxacin Hydrochloride Tablets 0.4 g, Po, QD, and the patients in the observation group were given 10 mg, Po, 1 times per night on the basis of the control group. The treatment course of the two groups was 6 D. compared to the two groups of patients with the cough symptom score, the peripheral leukocyte count (WBC) and the C reactive protein (CRP) content, the clinical efficacy and adverse reactions were observed. Results: before treatment, there was no significant difference between two groups of patients' cough symptom score, WBC and CRP content in peripheral blood (P0.05). After treatment, the score of cough symptoms in the two groups, the content of WBC and CRP in peripheral blood were significantly lower than that before treatment, and the score of cough symptoms after 3 D treatment in the observation group was significant The difference was statistically significant lower than that in the control group (P0.05), but there was no significant difference between the two groups after 6 D treatment (P0.05). The cure rate of the patients in the observation group was 64.29%, significantly higher than that of the control group (44.93%), the difference was statistically significant (P0.05); the effective rate of the observation group and the control group was 97.14%, respectively. And 97.10%, there was no significant difference between the groups (P0.05). There was no obvious adverse reaction in the two groups during the treatment and the clinical outcome was good. Conclusion: Montelukast Combined with moxifloxacin can not only effectively reduce the cough and inflammation of patients with acute bacterial bronchitis, but also improve the cure rate and safety. Higher.

【作者单位】：宁波市鄞州区钱湖医院内科;宁波大学附属医院呼吸内科;浙江省象山县红十字台胞医院内科;
【基金】：浙江省自然科学基金资助项目(No.LY15H010004)
【分类号】：R562.21

【相似文献】